High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
J Eur Acad Dermatol Venereol
; 36(8): 1308-1317, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-35462428
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dermatite Atópica
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Child
/
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article